QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=4DA2ED7BBCCA5CAD0216612FD8B5B135;jsessionid=402CD09D12027F9CEE86DE7EF9FFC046;jsessionid=F207DE96A5CEB97D510F0FCCB44213E9;jsessionid=0595184E88163C185B3B9D82B9FDA3EE;jsessionid=D989753AE7E7962297CDDA3AB5A45D85;jsessionid=4FBB1493B1CA8D1179B9ECDDFB1D7E23;jsessionid=E18980B334593AFEBFA005576DCA1301 (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=4DA2ED7BBCCA5CAD0216612FD8B5B135;jsessionid=402CD09D12027F9CEE86DE7EF9FFC046;jsessionid=F207DE96A5CEB97D510F0FCCB44213E9;jsessionid=0595184E88163C185B3B9D82B9FDA3EE;jsessionid=D989753AE7E7962297CDDA3AB5A45D85;jsessionid=4FBB1493B1CA8D1179B9ECDDFB1D7E23;jsessionid=E18980B334593AFEBFA005576DCA1301